| Cemtrex Inc. (NASDAQ: CETX) Webinar Tues. 11 Dec. 2018, 1 p.m. Eastern |
| |
|
Cemtrex Inc. (NASDAQ: CETX), a leading global technology and manufacturing company, will host an investor webinar and live Q&A session on Tuesday, December 11, 2018 at 1 p.m. Eastern.
The webinar will feature a presentation by Saagar Govil, CEO of Cemtrex. Govil will provide news on the Company’s flagship IoT product, SmartDesk, the world’s most advanced workstation.
To view the webinar, at 1 p.m. Tuesday click https://www.redchip.com/events/35/cemtrex-webinar. An archived version of the webinar will be on that page, for later viewing.
Disclosure
Cemtrex, Inc. (NASDAQ: CETX) agreed to pay RedChip Companies, Inc. a monthly cash fee for three (3) months of investor relation awareness services.
|
|
| |
|
| Shark Tank’s O’Leary Finds Small Caps the ‘Perfect Investment’ Over Next Few Years |
| |
|
Famed Shark Tank investor Kevin O’Leary sees more upside ahead for small cap stocks, calling them the “perfect investment over the next few years” as issues around trade get worked out and the positive impact of the tax cuts is realized, according to Kiplinger.
“I say there is 20% more cash to come to these companies in the next 24 months through tax reform, so I am staying on this trade,” O’Leary told CNBC back in August. “I am betting they continue to outperform not only the S&P 500, but maybe even emerging markets. There is tremendous value to be unlocked in small caps in America,” commented O’Leary.
|
|
| |
|
| Spectrum Pharmaceuticals (NASDAQ: SPPI) Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® |
| |
|
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced results from a prospective Phase 2 single-arm, open-label, multicenter clinical trial studying the management of oral mucositis with the use of oral leucovorin (d,l-folinic acid) as adjunct to FOLOTYN® (pralatrexate) in patients with hematological malignancies, including PTCL and CTCL.
Key Quote: “Mucositis is a frequent complication of FOLOTYN® therapy, which can cause painful inflammation of the digestive tract. It is often managed by omitting, delaying, or reducing the dose of this medication in some patients.” Andrei R Shustov, MD, lead investigator, professor of medicine, hematology, University of Washington School of Medicine, and hematologist, Seattle Cancer Care Alliance
The Backstory: Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets seven hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
|
|
| |
|
|
Nemaura (NASDAQ: NMRD) Completes Clinical Studies for SugarBEAT® FDA Submission |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) for use by people with diabetes and pre-diabetics, announced that it has successfully completed the clinical studies needed to support a De-Novo 510(k) submission to the U.S. Food & Drug Administration ("FDA") for approval of its sugarBEAT® product.
Why It Matters: The global addressable market for CGM is estimated at $82B per annum, with the U.S. market estimated at $13.5B. CGM adoption among people with diabetes is minimal and growing rapidly, with the U.S. the largest single market, with an estimated 2.6% (630,000 users) of all diagnosed diabetics using CGM in 2018, representing annualized growth of 117%. SugarBEAT® has the potential to differ from current CGM products and capture significant market share, given it is non-invasive, affordable, and flexible.
What’s Next: Nemaura has established the De-Novo 510(k) to be the most appropriate regulatory approval pathway for sugarBEAT®, and expects this route to be a potentially shorter pathway to regulatory approval for sugarBEAT®, as compared to a Pre Market Authorization (PMA). SugarBEAT® is also currently undergoing CE review and approval is anticipated in the coming weeks, followed by initial launch in the UK. The UK market for CGM is estimated at $1.38B per annum.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
|
Abeona Therapeutics (NASDAQ: ABEO) Details Pathway for Advancing Lead Clinical Programs
|
| |
|
Abeona Therapeutics Inc. (NASDAQ: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced key pipeline updates during the Company’s 2018 R&D Day.
Key Quote: “We are very pleased to share next steps for our lead programs and to unveil the potential of the novel AIMTM AAV vector platform that could be a catalyst for the next generation of gene therapy.” João Siffert, M.D., interim Chief Executive Officer, Chief Medical Officer and Head of R&D
The Backstory: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases.
|
|
| |
|
| Level Brands (NYSE American: LEVB) Signs Definitive Merger Agreement to Acquire Leading CBD Brand |
| |
|
Level Brands (NYSE American: LEVB), an innovative marketing and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses, signed a definitive merger agreement to acquire Cure Based Development, LLC, the owner, operator, and manufacturer of nationally recognized consumer cannabidiol (CBD) brand, cbdMD.
Why It Matters: Formed in August 2017, Cure Based Development began reporting revenues in 2018 and for the eight months ended August 31, 2018 reported revenue of $3.2 million and in October 2018 had monthly sales exceeding $1.0 million. Cure Based Development's current product offerings include gummies, tinctures, topical, bath bombs, oils, and pet products. Its products are available online at www.cbdMD.com or at 700 stores in 40 states. Cure Based Development currently employs over 50 people in its corporate, manufacturing, and distribution sites based in Charlotte, NC.
Key Quote: “With the passage of the 2018 Farm Bill, CBD will no longer be listed as a Schedule 1 controlled substance, which we believe will open the access to national retailers for CBD consumer products. We believe that the next three to five years will produce a few leading CBD brands, and our goal is to be the leader in the space." – Martin A. Sumichrast, Chairman and CEO
What’s Next: Following the expected closing, the operations of Cure Based Development will continue as a wholly owned subsidiary of Level Brands. In addition, Mr. Scott Coffman, the CEO of Cure Based Development, and Ms. Caryn Dunayer, its President, will continue in similar positions with our cbdMD LLC subsidiary. Following the closing, Mr. Coffman will also join Level Brands' Board of Directors. Mr. Coffman founded Ecig Company Blu in 2009 and built it into one the leading ECIG brands in the world before selling it to Lorillard Tobacco in 2012.
Disclosure
Level Brands (NYSE American: LEVB) is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee and 5,000 shares of Rule 144 stock for (3) months of RedChip investor awareness services.
|
|
| |
|
|
SSR Mining (NASDAQ: SSRM) Declares Commercial Production at the Chinchillas Mine
|
| |
|
SSR Mining Inc. (NASDAQ: SSRM) is pleased to announce it has declared commercial production at the Chinchillas mine as of December 1, 2018.
Key Quote: "Declaring commercial production at Chinchillas marks another major milestone as we continue to deliver growth and value for shareholders.” Paul Benson, President and CEO
The Backstory: SSR Mining Inc. is a Canadian-based precious-metals producer with three operations, including the Marigold gold mine in Nevada, the Seabee Gold Operation in Saskatchewan, Canada, and the 75%-owned and operated Puna Operations joint venture in Jujuy, Argentina.
|
|
| |
|
| |
| Quote of the Week |
| |
"Higher returns, of course, come with more risk...the trade off is, yes, you get long-term outperformance ... but the volatility of returns is greater... That's the price you pay if you want exposure to a better-performing asset class."
- Samuel Dedio, Manager of the Artio U.S. Microcap Fund (JMCAX) |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
Copyright © 2018 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
If you received this email by mistake you can unsubscribe from all emails.
|
|
|
|
|
